Prelude Therapeutics
PRLD • NASDAQ
Prelude Therapeutics is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Krishna Vaddi, with a market cap of $192.2M.
CEOKrishna Vaddi
Next Earnings
Upcoming earnings announcement for Prelude Therapeutics
Date
Tuesday, May 5, 2026 (in a month)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.29
Earnings History
Past 12 earnings reports for Prelude Therapeutics
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 10, 2026 | Q4 2025 | -$0.20Est: -$0.24 | +16.7% | $5.6MEst: $20.5M | -72.5% |  10-K |
| Nov 12, 2025 | Q3 2025 | -$0.26Est: -$0.35 | +25.7% | $6.5M | — | 10-Q |
| Aug 14, 2025 | Q2 2025 | -$0.41Est: -$0.44 | +6.8% | - | — | 10-Q |
| May 6, 2025 | Q1 2025 | -$0.42Est: -$0.47 | +10.6% | - | — | 10-Q |
| Mar 10, 2025 | Q4 2024 | -$0.37Est: -$0.47 | +21.3% | $4.0M | — | 10-K |
| Nov 6, 2024 | Q3 2024 | -$0.43Est: -$0.47 | +8.5% | $3.0M | — | 10-Q |
| Aug 12, 2024 | Q2 2024 | -$0.46Est: -$0.42 | -9.5% | - | — | 10-Q |
| May 7, 2024 | Q1 2024 | -$0.42Est: -$0.48 | +12.5% | - | — | 10-Q |
| Feb 15, 2024 | Q4 2023 | -$0.45Est: -$0.49 | +8.2% | - | — | 10-K |
| Nov 1, 2023 | Q3 2023 | -$0.45Est: -$0.58 | +22.4% | - | — | — |
| Aug 3, 2023 | Q2 2023 | -$0.54Est: -$0.63 | +14.3% | - | — | 10-Q |
| May 8, 2023 | Q1 2023 | -$0.58Est: -$0.68 | +14.7% | - | — | — |